Table 1.

Characteristics of 11 patients diagnosed with HIV in the framework of the SHOT Project in Sassari, Italy, from April 2017 until October 2018.

Patient	Sex	Age	Risk Factor	Reason for Testing	Opportunistic Infections	Stage	Basal HIV-RNA (Copies/mL)	CD4 Cells/mm3	CD4 %	CD4/CD8	First-Line Therapy	Date of Negativization	LTFU
1	Female	29	HE	Fever	None	B3	2,000,000	54.00	5.62	0.12	TDF/FTC + ATV/r	10 February 2018	Yes
2	Female	41	HE	Pharyngotonsillitis; Rash	None	A1	9420	1357.00	52.15	1.63	TDF/TAF + DTG	27 September 2019	No
3	Male	43	MSM	Bilateral pneumonia	PjP	C3	6480	56.00	3.14	0.04	TDF/FTC + DTG	8 November 2017	No
4	Female	42	HE	Bilateral pneumonia	PjP	C3	1,940,000	80.00	5.2	0.19	TDF/FTC + DTG	Died	No
5	Male	40	MSM	Bilateral pneumonia	PjP	A2	150,000	308.00	23.00	0.42	TDF/FTC + DTG	25 July 2017	No
6	Male	40	IDU	Bilateral pneumonia	PjP	C3	739,000	14.00	0.48	0.01	TDF/FTC + DTG	17 July 2017	No
7	Female	57	HE	Pleural Empyema	None	B2	139,000	317.00	10.72	0.14	TAF/FTC + RAL	21 March 2019	No
8	Male	72	HE	Fever; Asthenia	HZV	C3	462,000	162.00	17.97	0.62	TDF/FTC + RAL	16 March 2018	No
9	Male	66	HE	Fever; Asthenia	None	B1	765,000	924.00	9.77	1.39	TDF/FTC + DRV/r	12 September 2017	Yes
10	Male	28	MSM	Bilateral pneumonia	PCP; Invasive Pneumococcal Disease; CMV; Esophageal Candidiasis; Perianal HSV	C3	150,000	29.00	3.89	0.07	TDF/FTC + DTG	1 June 2017	No
11	Male	73	MSM	Stomatitis	None	B2	73,100	246.00	20.00	0.38	TDF/TAF + RAL	2 October 2019	No

LTFU: loss to follow up; HE: heterosexual; MSM: man who has sex with man; IDU: injective drug user; PjP: Pneumocystis jirovecii Pneumoniae; HZV: Herpes Zoster Virus; HSV: Herpes Simplex Virus; CMV: Cytomegalovirus; TDF: Tenofovir Disoproxil Fumarate; FTC: Emtricitabine; ATV/r: Atazanavir/ritonavir; TAF: Tenofovir Alafenamide Fumarate; DTG: Dolutegravir; RAL: Raltegravir; DRV/r: Darunavir/ritonavir.